Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Global E Online Ltd (GLBE) vs Viatris Inc (VTRS) Price & Performance

Global E Online LtdTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

Global E Online Ltd vs Viatris Inc — how do they compare? Global E Online Ltd trades at $40.8 (market cap $6.90B), while Viatris Inc trades at $16.28 (market cap $18.69B). The key difference: Viatris Inc is far larger — about 2.7× Global E Online Ltd's market cap, and Viatris Inc pays a 2.95% dividend while Global E Online Ltd pays none. Which is the better fit depends on your goals.

GLBEVTRS
Market Cap
$6.90B$18.69B
Sector
TechnologyHealth
52-Week High
$42.32$17.86
52-Week Low
$27.54$9.49
Enterprise Value
$6.37B$30.81B
Dividend Yield
2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Global E Online Ltd

GLBE trades at $42.32, up 3.17% in the past 24 hours, near its 52-week high. The stock shows bullish technical signals with strong moving average support, though RSI indicates overbought conditions. Recent earnings have been mixed, with a beat in Q4 2025 but a miss in Q1 2026. The company reported 2025 revenue of $962.20 million and net income of $68.27 million, with profitability improving into 2026. Key developments include the acquisition of Passport to enhance logistics capabilities and a $500 million share repurchase program authorized by the board.

GLBE presents a growth opportunity with robust analyst support—100% buy ratings and a consensus price target of $44.75, suggesting upside potential. However, risks include high valuation multiples like a P/E of 61.33, competitive pressures in e-commerce enablement, and insider selling by the CEO. Investors should weigh the strong growth trajectory against premium valuation and market volatility.

Viatris Inc

Viatris (VTRS) trades at $16.43, up 0.86% with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, with revenues rising 5% year-over-year. However, fundamental challenges persist with negative net income margin (-2.79%) and elevated P/E ratio (236.2). Recent developments include FDA approval for Gwyn Lo contraceptive patch and strategic divestitures to sharpen focus.

While Viatris shows operational improvements with consistent cash flow generation, the stock faces headwinds from profitability challenges and high valuation multiples. The mixed analyst sentiment (30.77% buy rating) reflects uncertainty about the company's turnaround trajectory. Key risks include ongoing margin pressure and competitive threats in the generic pharmaceutical space.

Returns comparison

Trailing returns across standard periods

About Global E Online Ltd

Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.

Read more on GLBE

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS